My family’s 6-year-old female German Shepherd was recently diagnosed with splenic hemangiosarcoma following an emergency splenectomy. She saw a veterinary oncologist today, and I’m hoping to get some additional professional perspectives on the recommended treatment plan.
Background:
Last week, my dog underwent emergency surgery after a golf ball-sized tumor on her spleen ruptured, causing significant internal bleeding. She lost approximately one-third of her blood volume, but the surgeon successfully removed her spleen and stopped the bleeding.
During surgery, the veterinarian also discovered numerous nodules on her liver, raising concerns about metastasis. One of the nodules was biopsied, although I don’t yet have confirmed results regarding whether the liver is involved.
Despite the severity of the situation, her postoperative recovery has been very encouraging. She initially had an elevated heart rate and declining red blood cell count, but her levels began improving without a transfusion. Before discharge, imaging showed no remaining blood in her abdomen. She’s now home recovering and doing well overall.
Oncology consultation and proposed treatment:
Today, my family met with a veterinary oncologist who recommended pursuing genomic testing and targeted immunotherapy rather than traditional chemotherapy. (I was not able to go, so pardon me if I use incorrect terminology.)
My understanding is that the recommendation was based partly on concerns about the potential side effects of conventional chemotherapy, particularly given the limited prognosis associated with hemangiosarcoma.
I’m still learning about the specifics of the proposed treatment, but I’m interested in understanding how this approach compares with the more conventional doxorubicin-based chemotherapy protocols.
Questions for veterinarians and veterinary oncologists:
How established is targeted immunotherapy for canine splenic hemangiosarcoma? Is it generally considered experimental, or is there meaningful evidence supporting its effectiveness?
How does the available evidence for immunotherapy compare with doxorubicin-based chemotherapy in terms of survival and quality of life?
Is avoiding traditional chemotherapy because of potential side effects a common recommendation? My understanding is that many dogs tolerate chemotherapy better than humans, so I’m curious about the reasoning.
Are there any recent studies, clinical trials, or treatment protocols we should discuss with her oncologist?
I completely understand that hemangiosarcoma is aggressive and that even with treatment, the prognosis is often poor. We’re not looking to pursue aggressive treatment simply to extend her life at the expense of her comfort.
Our primary goal is to maximize her quality of life while giving her as much meaningful time as possible.
I also recognize that no one can make a specific treatment recommendation without reviewing her complete medical records. I’m primarily hoping to understand the scientific evidence behind this approach and whether it aligns with current veterinary oncology practices.
I’d appreciate any professional insight, relevant research, or suggestions for questions to bring back to her oncologist. Thank you!